Abstract:The control of retroviral infection by antiviral factors referred to as restriction factors has become an exciting area in infectious disease research. TRIM5α has emerged as an important restriction factor impacting on retroviral replication including HIV-1 replication in primates. TRIM5α has a tripartite motif comprising RING, B-Box and coiled coil domains. The antiviral α splice variant additionally encodes a B30.2 domain which is recruited to incoming viral cores and determines antiviral specificity. TRIM5 is ubiquitinylated and rapidly turned over by the proteasome in a RING dependent way. Protecting restricted virus from degradation, by inhibiting the proteasome, rescues DNA synthesis, but not infectivity, indicating that restriction of infectivity by TRIM5α does not depend on the proteasome but the early block to DNA synthesis is likely to be mediated by rapid degradation of the restricted cores. The peptidyl prolyl isomerase enzyme cyclophilin A isomerises a peptide bond on the surface of the HIV-1 capsid and impacts on sensitivity to restriction by TRIM5α from Old World monkeys. This suggests that TRIM5α from Old World monkeys might have a preference for a particular capsid isomer and suggests a role for cyclophilin A in innate immunity in general. Whether there are more human antiviral TRIMs remains uncertain although the evidence for TRIM19's (PML) antiviral properties continues to grow. A TRIM5-like molecule with broad antiviral activity in cattle suggests that TRIM mediated innate immunity might be common in mammals. Certainly the continued study of restriction of viral infectivity by antiviral host factors will remain of interest to a broad audience and impact on a variety of areas including development of animal models for infection, development of viral vectors for gene therapy and the search for novel antiviral drug targets.

Evolution of Primates TRIM5 Gene and Anti-retrovirus Diversity

Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1

TRIM5α Modulates Immunodeficiency Virus Control in Rhesus Monkeys

Functional Analysis on the Anti-Hiv Activity of TRIM5α

TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques

TRIM5α: A Protean Architect of Viral Recognition and Innate Immunity

TRIM5α polymorphism identification in cynomolgus macaques of Vietnamese origin and Chinese rhesus macaques

The control of viral infection by tripartite motif proteins and cyclophilin A

Retroviral Restriction Factors Trim5 Alpha: Therapeutic Strategy To Inhibit Hiv-1 Replication

Recurrent evolution of an inhibitor of ESCRT-dependent virus budding and LINE-1 retrotransposition in primates

Targeting the rhesus macaque TRIM5α gene to enhance the susceptibility of CD4 + T cells to HIV-1 infection

Examination of the APOBEC3 Barrier to Cross Species Transmission of Primate Lentiviruses

Trim5 Alpha H43y Polymorphism And Susceptibility To Hiv-1 Infection: A Meta-Analysis

The cyclophilin A-binding loop of the capsid regulates the human TRIM5α sensitivity of nonpandemic HIV-1

An all-atom view into the disordered interaction interface of the TRIM5α PRYSPRY domain and the HIV capsid

The primate‐specific presence of interferon regulatory factor‐5 pseudogene 1

The Primate-Specific Presence of Interferon Regulatory Factor-5 Pseudogene 1

Tripartite motif proteins: an emerging antiviral protein family

Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G

PSGL-1 is an Evolutionarily Conserved Antiviral Restriction Factor.

Variation of two primate lineage-specific residues in human SAMHD1 confers resistance to N terminus-targeted SIV Vpx proteins.